Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

Bleeding in acquired hemophilia: have we figured it out?

Jean St-Louis

Blood (2020) 136 (3): 262–264.

https://doi.org/10.1182/blood.2020006098

Published: 2020

Journal Articles

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Katharina Holstein, Xiaofei Liu, Andrea Smith, Paul Knöbl, Robert Klamroth, Ulrich Geisen, Hermann Eichler, Wolfgang Miesbach, Andreas Tiede

Blood (2020) 136 (3): 279–287.

https://doi.org/10.1182/blood.2019003639

Published: 2020

Includes: Supplemental data

Journal Articles

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

German Alejandro Detarsio, Sr., BSc, Mariana Raviola, Mauro Davoli, MD, Maria Fabiana Garcia

Blood (2019) 134 (Supplement_1): 4936.

https://doi.org/10.1182/blood-2019-125977

Published: 2019

Journal Articles

Acquired Hemophilia and Plasma Cell Neoplasms, a Rare Association

Katarzyna Aleksandra Jalowiec, Martin Andres, Behrouz Mansouri Taleghani, Anne Angelillo-Scherrer, MD PhD, Alicia Rovo, Johanna A. Kremer Hovinga, MD Prof

Blood (2019) 134 (Supplement_1): 4930.

https://doi.org/10.1182/blood-2019-128048

Published: 2019

Journal Articles

Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4 + T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors

Ahmad Faisal Karim, PhD, Pooja Vir, PhD, Devi Gunasekera, MBBS, Allen I. Stering, MD, Kenneth Lieuw, MD PhD, Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 2413.

https://doi.org/10.1182/blood-2019-124803

Published: 2019

Journal Articles

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Ellen Cusano, Adrienne Lee, MD, Julia Hews-Girard, RN BScN MN

Blood (2019) 134 (Supplement_1): 2399.

https://doi.org/10.1182/blood-2019-129665

Published: 2019

Journal Articles

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

Jevgenia Zilberman-Rudenko, Hiroshi Deguchi, MD PhD, Mohammed Hayat, Meenal Shukla, PhD, Jennifer Nagrampa Orje, Zihan Guo, Tine Wyseure, PhD, Laurent O Mosnier, Owen J T McCarty, PhD, Zaverio M. Ruggeri, MD, John H. Griffin, PhD

Blood (2019) 134 (Supplement_1): 3632.

https://doi.org/10.1182/blood-2019-129312

Published: 2019

Journal Articles

All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia Α Patients in the United States

Ming Y. Lim, MBBChir,MA, Dunlei Cheng, PhD, Christine L. Kempton, MD MSc, Nigel S. Key, MBChB, FRCP

Blood (2019) 134 (Supplement_1): 902.

https://doi.org/10.1182/blood-2019-122991

Published: 2019

Journal Articles

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Carolyne Elbaz, MD, Katerina Pavenski, MD, Hina Chaudhry, BSc, Jerome M. Teitel, MD FRCPC, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 1128.

https://doi.org/10.1182/blood-2019-122260

Published: 2019

Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Paul Knoebl, MD, Wolfgang R. Sperr, Peter Schellongowski, MD, Thomas Staudinger, MD, Petra Jilma-Stohlawetz, MD, Peter Quehenberger, MD, Silvia Koder, Ing, Cihan Ay, MD, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 2476.

https://doi.org/10.1182/blood-2018-99-116973

Published: 2018

Journal Articles

Overshoot of FVIII Activity in Patients with Acquired Hemophilia

Yoshiyuki Ogawa, MD PhD, Kunio Yanagisawa, MD PhD, Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Akitada Ichinose, MD PhD, Hiroshi Handa, MD PhD

Blood (2018) 132 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2018-99-112126

Published: 2018

Journal Articles

Recombinant Porcine FVIII in Acquired Hemophilia: Decreased Product Usage When Used Upfront, Non-Utility of Baseline Porcine Bethesda Titer, and Confirmation of Dosing Algorithm

Patrick Ellsworth, MD, Sheh-Li Chen, PharmD, Nigel S. Key, MBChB, FRCP, Raj S. Kasthuri, MD, Micah J. Mooberry, MD, Alice D. Ma, MD

Blood (2018) 132 (Supplement 1): 2474.

https://doi.org/10.1182/blood-2018-99-118839

Published: 2018

Journal Articles

Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy

Patrick Ellsworth, MD, Sheh-Li Chen, PharmD, Yasmina L. Abajas, MD, Stephan Moll, MD, Nigel S. Key, MBChB, FRCP, Alice D. Ma, MD

Blood (2018) 132 (Supplement 1): 1202.

https://doi.org/10.1182/blood-2018-99-119196

Published: 2018

Journal Articles

Thrombotic Events with NovoSeven ® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs

Madhvi Rajpurkar, MD, Stacy E. Croteau, MD, Lisa N Boggio, MD MS, David L Cooper, MD

Blood (2018) 132 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2018-99-115153

Published: 2018

Journal Articles

Transplacental Hemophilia a and Prophylactic Treatment with Recombinant FVIIa in the Newborn Period

Selin Aytac, Tolga Celik, Sule Yigit, Fatma Gumruk, MD

Blood (2018) 132 (Supplement 1): 5024.

https://doi.org/10.1182/blood-2018-99-119760

Published: 2018

Journal Articles

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

Heidi Chwan Ko, DO, Cristhiam Rojas Hernandez, MD, Thein Hlaing Oo, MD

Blood (2017) 130 (Supplement 1): 5639.

https://doi.org/10.1182/blood.V130.Suppl_1.5639.5639

Published: 2017

Journal Articles

United States Post-Marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Data

R. Crea, DVM, MSc, Jui-Fu Huang, Naghmana Bajwa, Alessandro Gringeri, MD PhD

Blood (2017) 130 (Supplement 1): 3686.

https://doi.org/10.1182/blood.V130.Suppl_1.3686.3686

Published: 2017

Journal Articles

Successful Treatment of Bleeding in Acquired Hemophilia A with Activated Prothrombin Complex Concentrate in Spain

Maria Eva Mingot-Castellano, PhD MD, Rocio Pérez-Montes, MD, Mariana Canaro, PhD MD, Ana Marco, PhD MD, Victoria Calle-Gordo, MD, Ana Isabel Heiniger, MD

Blood (2017) 130 (Supplement 1): 3688.

https://doi.org/10.1182/blood.V130.Suppl_1.3688.3688

Published: 2017

Journal Articles

Epidemiology and Management of Acquired Hemophilia A in a Single Hospital System

Amar Kelkar, MD BS, Annia Martial, MD BSc, Jason Morell, PharmD, Shylendra Sreenivasappa, MD MPH

Blood (2017) 130 (Supplement 1): 4870.

https://doi.org/10.1182/blood.V130.Suppl_1.4870.4870

Published: 2017

Journal Articles

Influence of Inhibitor Characteristics on Response to Hemostatic and Immunosuppressive Treaments in Acquired Hemophilia Patients: The Ciha Project

Maria Eva Mingot, PhD MD, Pascual Marco-Vera, PhD MD, Andrés Moret, PhD MD, Carmen de Cos, MD, Faustino García-Candel, PhD MD, Raquel Garrido, MD, Jose Ramon González-Porras, MDPhD, María Fernanda López, PhD MD, Laura Quintana, MD, Ramon Rodríguez-González, MD, Ana Isabel Heiniger, MD

Blood (2017) 130 (Supplement 1): 2367.

https://doi.org/10.1182/blood.V130.Suppl_1.2367.2367

Published: 2017

NARROW

Bleeding in acquired hemophilia: have we figured it out?

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

Acquired Hemophilia and Plasma Cell Neoplasms, a Rare Association

Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4 + T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors

Case Series: Outcome and Cost Analysis of Rituximab Versus Non-Targeted Immunosuppression As First Line Inhibitor Eradication in Acquired Hemophilia a

Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo

All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia Α Patients in the United States

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Overshoot of FVIII Activity in Patients with Acquired Hemophilia

Recombinant Porcine FVIII in Acquired Hemophilia: Decreased Product Usage When Used Upfront, Non-Utility of Baseline Porcine Bethesda Titer, and Confirmation of Dosing Algorithm

Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy

Thrombotic Events with NovoSeven ® RT in Approved Indications Are Rare (0.2%) and Associated with Older Age (>= 65 y), Cardiovascular Disease, and Concomitant Use of aPCCs

Transplacental Hemophilia a and Prophylactic Treatment with Recombinant FVIIa in the Newborn Period

Clinical Outcomes of Acquired Factor VIII Inhibitors in Cancer Population: A Systematic Review

United States Post-Marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Data

Successful Treatment of Bleeding in Acquired Hemophilia A with Activated Prothrombin Complex Concentrate in Spain

Epidemiology and Management of Acquired Hemophilia A in a Single Hospital System

Influence of Inhibitor Characteristics on Response to Hemostatic and Immunosuppressive Treaments in Acquired Hemophilia Patients: The Ciha Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only